The race towards oral weight loss medication has taken another significant turn, and patients across the UK are already asking what it means for them. Foundayo, the brand name for orforglipron, has just been approved in the UK, a genuine milestone in obesity medicine.
At Everest Pharmacy, we like to stay ahead of developments like this so our patients are never left playing catch-up. We also work closely with our online sister site, Everslim, and we can confirm that Foundayo is available via Everslim’s online consultation platform, following the same clinical standards we apply to every treatment we offer.
This guide explains exactly what Foundayo is, how it differs from existing GLP-1 treatments, what the clinical trial data shows, and why UK patients should consider this new weight loss option. If you have questions or if you would rather get started with weight loss treatment, contact our team today.
What Is Foundayo?
Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist developed by Eli Lilly. It belongs to the same family of medicines as Wegovy (semaglutide) and Mounjaro (tirzepatide), but unlike those two, it does not need to be injected. It was approved by the US Food and Drug Administration on 1 April 2026, making it only the second GLP-1 pill ever approved for weight loss, following Novo Nordisk’s Wegovy pill (oral semaglutide) in December 2025.
What sets Foundayo apart is that it can be taken at any time of day, with or without food, and without any water restrictions. No other oral GLP-1 medicine currently shares this flexibility, and this is a direct result of how the medicine itself is built, rather than a marketing claim.
Why Foundayo Works Differently To Wegovy And Mounjaro
Most GLP-1 medicines, including semaglutide and tirzepatide, are peptides. Peptides are chains of amino acids that are easily broken down by stomach acid, which is why Wegovy and Mounjaro are given as injections rather than tablets. The Wegovy pill gets around this using a special absorption enhancer, but only works if taken on an empty stomach with a small sip of water, thirty minutes before anything else.
Foundayo takes a different approach entirely. It is a small molecule rather than a peptide, meaning it is a simpler, more stable compound that survives digestion and absorbs reliably regardless of food or drink. This is the reason it can be taken flexibly throughout the day, and it is also why manufacturing is expected to be more straightforward and scalable than the complex biological processes required for peptide-based medicines like Wegovy and Mounjaro.
The Evidence Behind Foundayo: The ATTAIN Trials
Foundayo’s approval was supported by the ATTAIN phase 3 clinical trial programme, which enrolled more than 4,500 participants with obesity or overweight. A few key findings stand out:
-
- In ATTAIN-1, which studied adults with obesity but without type 2 diabetes, patients on the highest dose who remained on treatment lost an average of 12.4% of their body weight over 72 weeks, compared with 0.9% on placebo
- In ATTAIN-2, which studied adults with obesity and type 2 diabetes, patients on the highest dose lost an average of 10.5% of body weight, and HbA1c fell by up to 1.8 percentage points from baseline
- The ATTAIN-MAINTAIN trial specifically looked at whether patients who had already lost weight using injectable GLP-1s could switch to Foundayo for long-term weight maintenance, with early results suggesting this may be a viable approach
- A head-to-head trial called ACHIEVE-3 compared Foundayo directly with oral semaglutide in adults with type 2 diabetes, finding Foundayo produced greater reductions in HbA1c and slightly higher weight loss, though with somewhat higher rates of gastrointestinal side effects and discontinuation
How Effective Is Foundayo Compared To Other GLP-1 Treatments?
Foundayo works, but it does not match the strongest injectable GLP-1 currently available on raw weight loss figures. At the highest approved doses over 72 weeks in clinical trials:
| Treatment | Average Weight Loss | Format | Food Restrictions |
|---|---|---|---|
| Mounjaro (tirzepatide) | Around 20 to 22% | Weekly injection | None |
| Wegovy injection (semaglutide) | Around 15% | Weekly injection | None |
| Wegovy pill (oral semaglutide) | Around 13 to 15% | Daily pill | Empty stomach, 30 minutes before food |
| Foundayo (orforglipron) | Around 11 to 12% | Daily pill | None |
Foundayo’s efficacy sits at the lower end of the GLP-1 spectrum, but a 10 to 12% average weight loss is still clinically meaningful, and considerably more than any non-GLP-1 weight loss medication typically achieves. For many patients, the convenience of a once-daily pill with no restrictions may outweigh the additional few percentage points of weight loss available from injectable options.
How Foundayo Is Dosed
Like other GLP-1 medicines, Foundayo is introduced gradually, starting at a low dose and increasing over several months to help the body adjust and reduce the likelihood of side effects. The FDA-approved US dosing schedule moves through six steps over roughly five months, with a minimum of thirty days at each dose:
-
- Step one: 0.8 mg once daily for thirty days
- Step two: 2.5 mg once daily for thirty days
- Step three: 5.5 mg once daily for thirty days
- Step four: 9 mg once daily for thirty days
- Step five: 14.5 mg once daily for thirty days
- Step six: 17.2 mg once daily as the ongoing maintenance dose
Not every patient needs to reach the highest dose, and prescribers can hold a patient at a lower dose if it is working well, or slow the titration down if side effects become difficult to manage. The tablet is swallowed whole and should not be broken, crushed, or chewed.
Foundayo was made available in the UK on 24th August. Our team can assess your eligibility today for this and other available, MHRA-licensed treatments such as Mounjaro or Wegovy, so you can start making progress with your weight loss journey.
Side Effects To Be Aware Of
Foundayo’s side effect profile is broadly consistent with other GLP-1 medications. The most commonly reported side effects in clinical trials included:
-
- Nausea, diarrhoea, and vomiting
- Constipation and abdominal bloating
- Indigestion and heartburn
- Headache and fatigue
- Hair loss, which may relate to the rate of weight loss itself rather than being a specific effect of the medication
Most gastrointestinal side effects are mild to moderate, appear most often during the dose escalation stages, and tend to settle as the body adjusts. Serious but rarer risks include pancreatitis, gallbladder problems, and kidney problems linked to severe dehydration from persistent vomiting or diarrhoea. As with other GLP-1 medicines, Foundayo carries a warning regarding thyroid C-cell tumours observed in animal studies, and it is not recommended for anyone with a personal or family history of medullary thyroid carcinoma.
Who Might Not Be Suitable For Foundayo
As with any GLP-1 medication, Foundayo will not be suitable for everyone. Based on current data, it is generally not recommended for those who:
-
- Have a personal or family history of medullary thyroid carcinoma
- Have Multiple Endocrine Neoplasia syndrome type 2
- Have a history of pancreatitis
- Have significant liver or kidney impairment
- Are pregnant, planning a pregnancy, or breastfeeding
- Have a history of eating disorders
- Are already taking another GLP-1 receptor agonist, such as Mounjaro or Wegovy
A prescriber will always assess individual Foundayo eligibility, typically requiring a BMI of 30 or above, or 27 and above alongside a weight-related health condition.
Why The Foundayo Launch Matters For UK Patients
The Foundayo launch matters for a few clear reasons:
-
- It removes the needle barrier: Many patients who could benefit from GLP-1 treatment avoid it purely because of needle anxiety. Foundayo, like the Wegovy pill, opens the door to people who would never consider self-injecting.
- It offers more flexibility than the Wegovy pill: The Wegovy pill must be taken on an empty stomach with minimal water thirty minutes before food. Foundayo has no such restrictions, which may make it easier for some patients to stay consistent with treatment.
- It may support long-term weight maintenance: The ATTAIN-MAINTAIN trial specifically tested whether patients who had already lost weight on injectable GLP-1s could switch to Foundayo afterwards, which is relevant for anyone currently on Mounjaro or Wegovy thinking about their longer-term plan.
- Supply is expected to be more reliable: As a small-molecule tablet, Foundayo can be manufactured using conventional processes, rather than the complex biological manufacturing required for peptide medicines. This may help avoid the kind of supply shortages that have affected injectable GLP-1s in the UK.
What To Do While You Wait: Foundayo Coming Soon To Everslim
If you are considering weight loss treatment now, there is no need to put your plans on hold while we get ready to launch Foundayo on our weight loss site. Everest Pharmacy and our online sister site, Everslim, can assess you today for currently available, MHRA-licensed alternatives, including:
-
- Mounjaro (tirzepatide), currently the most effective GLP-1 treatment available in the UK, with average weight loss figures notably higher than early Foundayo data
- Wegovy injection (semaglutide), a well-established option with years of real-world UK patient data
- Wegovy pill (oral semaglutide), which is expected to remain the first licensed oral GLP-1 option in the UK, potentially arriving before Foundayo
Foundayo itself is coming soon to Everslim, and patients can register their interest now to be notified the moment it becomes available, so there is no need to search elsewhere or risk unverified sellers in the meantime.
Whichever route you are exploring, our related guide on Wegovy vs Mounjaro may help you compare the two most established injectable options, and our article on weight loss injections offers useful background if you would like to start sooner rather than wait.
Frequently Asked Questions
Why has Foundayo attracted so much attention compared to other weight loss pills?
It is the first GLP-1 weight loss tablet with no food or water restrictions, meaning patients can take it at any time of day without planning meals around it, unlike other oral GLP-1 options.
Will Foundayo replace the need for weight loss injections altogether?
Unlikely in the short term. Injectable options such as Mounjaro currently produce greater average weight loss, so many patients may still prefer injections where maximum effectiveness is the priority.
Is Foundayo suitable for people who have never used a GLP-1 medicine before?
This will depend on individual assessment once it launches in the UK. GLP-1 medicines are not usually a first-line treatment and are generally considered after lifestyle measures alone have not achieved the desired results.
What makes Foundayo easier to manufacture than injectable GLP-1 medicines?
As a small molecule rather than a peptide, Foundayo can be produced using standard pharmaceutical manufacturing processes, avoiding the complex biological production methods that have contributed to supply shortages of injectable treatments.
Could Foundayo be used by patients coming off Mounjaro or Wegovy?
Early ATTAIN-MAINTAIN trial results suggest Foundayo may help with long-term weight maintenance after stopping an injectable GLP-1, though this would need individual clinical assessment once available in the UK.
Do I need to change my daily routine to take Foundayo?
No. Unlike the Wegovy pill, Foundayo has no food or water restrictions, so it can be taken at any time of day, alongside meals, drinks, or other medications, without needing to plan your morning around it.
Are there any long-term risks specific to Foundayo that differ from other GLP-1s?
Current evidence suggests a similar risk profile to other GLP-1 medicines, including thyroid and pancreatic warnings, though longer-term real-world monitoring will build a fuller picture over time.
Stay Informed About The Foundayo Launch With Everest Pharmacy
The Foundayo launch represents a genuinely exciting development in oral weight loss medication, and we are here to support UK patients. Whether you are considering Foundayo or starting treatment with an existing option, our team is here to guide you.
Contact us today to discuss your options, or book an appointment in-clinic or start a consultation with Everslim to explore existing weight loss treatments.